VIELA BIO

A clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease

Learn More

Our Portfolio

Viela Bio is building a portfolio of innovative biologics that either are first in class or have the potential to be best in class

Our Team

Viela Bio is led by a team of motivated industry experts, aiming to make a difference for inflammation and autoimmunity patients

Our Recent News

Viela Bio Appoints Mitchell Chan as Chief Financial Officer

| Company General News | No Comments
Gaithersburg, MD—July 1, 2019 – Viela Bio today announced the appointment of Mitchell Chan as Chief Financial Officer, effective July 1. In this role, he will be responsible for leading…

Viela Bio Closes $75 Million Series B Financing

| Company General News | No Comments
Financing led by HBM Healthcare Investments Gaithersburg, MD—June 17, 2019 – Viela Bio today announced the successful completion of a $75 million private placement of its Series B preferred stock,…

Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic Cancers in China

| Company General News | No Comments
Viela Bio is eligible to receive an upfront collaboration fee and milestone payments of more than $220 million plus royalties on product sales Gaithersburg, MD—May 28, 2019 – Viela Bio,…

Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting

| Company General News | No Comments
Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting Company to hold…